IDEAYA Biosciences, Inc. (IDYA)

Market Cap	2.91B
Revenue (ttm)	7.00M
Net Income (ttm)	-331.80M
Shares Out	87.64M
EPS (ttm)	-3.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,387,957
Open	32.58
Previous Close	32.37
Day's Range	32.39 - 33.64
52-Week Range	13.45 - 33.64
Beta	0.14
Analysts	Buy
Price Target	48.20 (+45.22%)
Earnings Date	Nov 4, 2025

About IDYA

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: IDYA
• Website: https://www.ideayabio.com

Financial Performance

In 2024, IDEAYA Biosciences's revenue was $7.00 million, a decrease of -70.07% compared to the previous year's $23.39 million. Losses were -$274.48 million, 143.0% more than in 2023.

Analyst Summary

According to 17 analysts, the average rating for IDYA stock is "Buy." The 12-month stock price target is $48.2, which is an increase of 45.22% from the latest price.

Price Target

$48.2

(45.22% upside)

Analyst Consensus: Buy